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Background: Breast cancer sensitivity to large fraction size may be enhanced using hypofractionated con-
comitant boost radiotherapy (CBRT), thereby shortening overall treatment time. This ethics approved,
prospective single cohort feasibility study was designed to evaluate the dosimetry and toxicity of CBRT
using an intensity-modulated radiotherapy (IMRT) technique, compared with a standard sequential boost
technique (SBT).
Methods: Fifteen women (11 right-sided; 4 left-sided) received 42.4 Gy to the whole breast and an addi-
tional 10.08 Gy to the tumor bed in 16 daily fractions, using IMRT and standard dose constraints. Each
patient was replanned with the SBT, using mixed photon–electrons. Clinical target volume (CTV), dose
evaluation volume (DEV), and organs at risk (OAR) dose distributions were compared with the SBT. Tox-
icity and treatment times were prospectively recorded.
Results: All 15 CBRT plans achieved the desired CTV (V49.9GyP 99%) and DEV (V49.9GyP 95%), coverage of
the boost, compared with only 10 (66.7%, p = 0.03), and 12 (80%, p = 0.125) SBT plans, respectively. Ipsi-
lateral lung (p < 0.0001), and heart (right-sided, p = 0.001; left-sided, p = 0.13) doses were lower. Grade 3
acute toxicity occurred in 1 (6.7%) patient. At 1 year, two (13.3%) additional patients had overall grade 2
late toxicity, compared with baseline. No grade 3–4 late toxicity was observed.
Conclusions: CBRT using IMRT improved boost coverage and lowered OAR doses, compared with SBT.
Toxicities were acceptable using a daily boost of 3.28 Gy. While resource utilization was greater, overall
treatment time was reduced.
 2011 Elsevier Ireland Ltd.Open access under CC BY-NC-ND license.
Radiotherapy and Oncology 102 (2012) 89–95Breast conservation surgery (BCS) followed by adjuvant whole
breast radiotherapy (WBI) remains the standard of care for early-
stage breast cancer, with a proven local control beneﬁt associated
with a gain in overall survival in a recent large meta-analysis [1].
Two randomized studies found that a sequential radiotherapy
boost to the tumor cavity further reduces local recurrences [2,3].
Consequently, boost RT is a widely accepted practice in patients
at higher risk for local recurrence, particularly younger patients,
and those with close surgical margins.
The optimal dose, fractionation schedule, delivery method, and
timing of the boost, remains as yet undeﬁned. The updated results
of the EORTC 22881 study, with a median follow-up of 10.8 years,
demonstrate a highly signiﬁcant reduction in local recurrence rates
for patients randomized to a sequential boost of 16 Gy in eightRadiation Oncology, Princess
niversity Avenue, Toronto,
e.walsh@rmp.uhn.on.ca (F.-F.
er CC BY-NC-ND license.fractions, compared to those receiving no boost (6.2% vs. 10.2%,
p < 0.0001) [2]. The rate of severe ﬁbrosis in those receiving a boost
was increased however, (4.4% vs. 1.6%, p < 0.0001). Similarly, Rom-
estaing et al. reported that an additional boost of 10 Gy in 2 Gy dai-
ly fractions was associated with lower rates of local recurrence at
5 years (3.6% vs. 4.5%, p = 0.044), but with increased rates of grades
1 and 2 telangiectasia (12.4% vs. 5.9%) [3].
Mounting evidence supports the theory that breast cancer cells
are in fact more sensitive than most other tumors to the effects of
fraction size, with a low a/b ratio of 4 Gy, similar to that of late
reacting normal tissue (typically a/b ratio of 3.4 Gy) [4–6]. Epithe-
lial tumors with a high estimated a/b ratio (10 Gy) are relatively
insensitive to fractionation effects, while tumors with low a/b
ratios are more sensitive to large fraction sizes. Consequently,
fewer larger fractions (hypofractionation) might be as or more efﬁ-
cacious, than many smaller fractions, without necessarily increas-
ing toxicity. However, with larger fraction sizes, the overall total
dose must be reduced to avoid excess late normal tissue toxicity.
Hypofractionated regimens have been studied in four large ran-
domized trials of more than 7000 invasive breast cancer patients,
90 Hypofractionated concomitant breast boostshowing comparable tumor control rates and long-term toxicity,
compared to conventional radiotherapy regimens using 2 Gy frac-
tions [7–10]. Hypofractionation for in situ disease has yielded
equally favorable results [11].
Many centers have adopted hypofractionated breast radiother-
apy as the standard for WBI. It is unclear how best to incorporate a
boost into this hypofractionated schema, particularly from a radio-
biological perspective. Three of the four randomized trials allowed
a sequential boost, which typically consisted of ﬁve conventional
fractions of 2 Gy each delivered with en face electrons. A hypofrac-
tionated concomitant boost regimen was designed to exploit the
fractionation sensitivity of breast cancer cells, as a primary objec-
tive for this study.
Numerous boost delivery techniques have been described,
including direct electrons, tangential photons, mixed electron/pho-
tons, interstitial brachytherapy, intra-operative approaches, and
intensity modulated radiotherapy (IMRT). IMRT has been shown
to reduce rates of acute radiation dermatitis during WBI, and is
in widespread use in many centers worldwide, including our
own institution [12,13]. We evaluated the feasibility of delivering
concomitant boost radiotherapy (CBRT) using inversely-planned
IMRT, with cone beam computed tomography (CBCT) veriﬁcation.
The primary end-points of this Phase I/II, prospective single-co-
hort clinical feasibility study were: (1) to compare the feasibility of
delivery, and resulting dose distributions to the target and organs
at risk (OAR), using CBRT with an IMRT technique, compared with
a standard sequential boost technique (SBT); (2) to determine
acute and late morbidities using a hypofractionated boost of
10.08 Gy delivered concomitantly over 16 fractions (total tumor
bed dose = 3.28 Gy per fraction). The secondary endpoint was re-
source utilization for CBRT.Methods and materials
Patient selection and evaluation
Between October 2008 and April 2009, 15 women aged
P18 years, with ductal carcinoma in situ (DCIS) or invasive carci-
noma (T0–T3 N0–N1), treated with BCS were recruited for this
study. Patients were required to have at least one indication for a
boost, deﬁned as: age 660 years, surgical margins 62 mm, lym-
phovascular space invasion, or extensive intraductal disease (DCIS
>25% of tumor volume). Patients were excluded if regional nodal
irradiation was required, mastectomy had been performed, distant
metastatic disease was identiﬁed, and if the surgical cavity could
not be clearly delineated on the CT-simulation scan, or occupied
>30% of total ipsilateral breast volume. Full written informed con-
sent was obtained for all patients and the study was approved by
the institutional Research Ethics Board.Surgery and systemic treatment
All patients had undergone BCS and sentinel node biopsy and/or
axillary nodal dissection. No titanium clips were placed in the sur-
gical cavity, as is the standard procedure at our institution. Re-
excision was recommended for close or positive resection margins
(deﬁned as 62 mm from the inked margin or tumor cells at the
margin, respectively). Systemic chemotherapy was administered
for high risk patients. Adjuvant endocrine therapy and trast-
uzumab were administered when indicated.Patient simulation and image acquisition
Radiation planning and treatment commenced within 12 weeks
of the last surgical procedure, or within 8 weeks of the ﬁnal che-
motherapy. CT-simulation was performed with patients in a supineposition, immobilized on a MT-350 carbon ﬁber breast board (CIV-
CO Medical Solutions, Kalona, Iowa), with the ipsilateral arm ab-
ducted and raised over-head. The surgical scar and clinically
palpable breast tissue were demarcated with radio-opaque wires,
and reference indicators tattooed. Imaging was performed by a
Brilliance CT Scanner (Brilliance, Philips Medical Systems, Bothell,
WA), and acquired in 2 mm slices from mid-neck to 5 cm below
the lungs. The CT dataset was exported to the treatment planning
system, Pinnacle version 8 (Philips Radiation Oncology Systems,
Milpitas, CA).Deﬁnition of target volumes and organs at risk
The ipsilateral whole breast was delineated by a radiation
oncologist and approved independently by another, both experts
in breast radiotherapy. This was denoted CTVbreast and consisted
of the volume of mammary tissue extending from, but excluding,
the pectoralis muscle to the skin. The ribs and superﬁcial 5 mm
of skin were also excluded. The surgical cavity, depicted by the ser-
oma evident on the simulation-CT was contoured, supplemented
by information from the operative note and pre-operative diagnos-
tic imaging. The boost clinical target volume (CTVboost) was deﬁned
as 5 mm of breast tissue beyond the delineated surgical cavity to
include possible microscopic disease, but excluding 5 mm from
the skin surface, pectoralis muscle and chest wall. To account for
set-up errors and respiration, 5 mm was added to create the plan-
ning target volume (PTVboost) [14]. For planning and dose evalua-
tion purposes, a dose evaluation volume (DEVboost) was created
to avoid dose build-up near the skin surface and lung, by trimming
the PTVboost at the chest wall and pectoralis muscle, as well as
5 mm from the skin surface.
The contralateral breast and lungs were delineated, and the
heart was contoured from the apex to the pulmonary trunk.Radiobiologic rationale
A biologically equivalent dose (BED) was calculated using the
linear-quadratic model, to compare the CBRT and SBT fractionation
schedules (Table 1). Potential doubling time (Tpot) and the effect of
total treatment time (Tt) effects were excluded to simplify analysis
and due to negligible repopulation effects for a 3.2 week CBRT
treatment schedule. We used a/b of 10 Gy for acute normal tissue
effects and a/b of 3.4 Gy for late tissue effects. In keeping with the
evidence supporting the low a/b of breast cancer, a/b of 4 Gy was
utilized for tumor control. The standard sequential boost fraction-
ation schedule prescribed in our institution is 10–16 Gy using 2 Gy
fractions, following WBI of 42.4 Gy in 16 fractions of 2.65 Gy each.
As many centers use a 2 Gy fractionation schedule for both WBI
and the boost, these calculations are included in Table 1. We se-
lected a boost dose of 3.28 Gy per fraction, as this compared closely
in terms of BED for tumor control and late toxicity with that of the
EORTC trial, which used eight fractions of 2 Gy each.Treatment planning technique – whole breast irradiation
WBI was delivered using standard medial and lateral tangents
with a semi-automated inverse-planned ‘step and shoot’ IMRT
technique, previously described [15]. Beam placement was based
upon the delineated CTVbreast and guided by the radio-opaque
markers on simulation-CT. The user deﬁned a medial and lateral
beam aperture that included the entire whole breast volume with
skin ﬂash. The user-deﬁned apertures were then incorporated into
the IMRT optimization and segments were also generated using in-
verse planning. The user-deﬁned segment was combined with the
segments into a single ﬁeld (for single energy plans) with the user-
deﬁned segment receiving typically 75–85% of the beam weight.
Table 1
Comparison of fractionation schedules.
Schedule
name
Whole breast
fractionation
Boost
fractionation
Total no.
fractions
Nominal total dose
PTVboost (Gy)
BED tumor control (Gy)
(a/b 4 Gy)a
BED acute effects (Gy)
(a/b 10 Gy)a
BED late effects (Gy)
(a/b 3.4 Gy)a
CBRT 2.65 Gy  16 3.28 Gy  16 16 52.48 95.51 69.69 103
SBT 2.65 Gy  16 2 Gy  8 24 58.4 93.88 72.59 100.14
SBT 2.65 Gy  16 2 Gy  5 21 52.4 85.15 65.5 91
Other 2.00 Gy  25 2 Gy  8 33 66 99 79.2 105
Other 2.00 Gy  25 2 Gy  5 30 60 90 72 95.3
a BED (biologically equivalent dose) calculations are for dose prescribed to PTVboost.
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95% WBI dose (40.3 Gy); a maximum of 2 cm3 of CTVbreast receives
more than 107% boost dose (56.2 Gy) [15].
For treatment delivery, an Elekta Synergy X-ray Volume Imag-
ing (XVI) system (Elekta, Stockholm, Sweden) with CBCT capability
was used for all patients. Treatment position was veriﬁed daily
using clinical assessments with treatment light ﬁelds and mega-
voltage electronic portal imaging prior to WBI, with a 5 mm action
threshold for WBI.Treatment planning boost technique – CBRT
CBRT was delivered immediately after each WBI fraction, deliv-
ering an additional 10.08 Gy boost in 16 daily fractions of 0.63 Gy
each, resulting in a total dose (including boost) of 52.4 Gy in 16
daily fractions (3.28 Gy/fraction). The concomitant boost was
planned with 3–4 non-coplanar photon beams (lateral, medial,
inferoanterior, and superoanterior obliques), selected to maximize
conformality of the boost volume and avoidance of OARs. The plan-
ning objectives used were: a maximum of 30% of the treated vol-
ume not within 1 cm of PTVboost receives more than 107% of WBI
dose (45.5 Gy); a maximum of 40% of the CTVbreast receives more
than 95% boost dose (49.9 Gy).
CBRT plans were evaluated and compared with SBT plans using
the following criteria: 99% of CTVboost by 95% of the boost dose
(49.9 Gy); and 95% of DEVboost by 95% of the boost dose
(49.9 Gy); OAR dose constraints for heart, lungs and contralateral
breast are summarized in the results section. CBCT imaging for
localization was performed prior to each boost fraction, since the
cavity is poorly visualized with CBCT, the lung, whole breast and
external volumes were used for matching purposes. The action tol-
erance used was 3 mm. This differs from our previous imaging
workﬂow for accelerated partial breast irradiation (APBI) in which
the action threshold was 5 mm [14]. With APBI, a larger tolerance
was accepted as per the RAPID study protocol, as a 10 mm set-up
uncertainty margin was used; whereas a 5 mm set-up uncertainty
margin is used in the current study.Treatment planning boost technique – standard boost
For comparison purposes, the boost was re-planned using a
standard mixed electron–photon beam technique, with the aim
of meeting the same target and normal tissue constraints as de-
ﬁned for CBRT-IMRT. This is the most frequently used technique
at our institution, delivering 10 Gy over ﬁve daily fractions of
2 Gy each (6 Gy with electrons; 4 Gy with photons). Analyses of
dose-volume parameters were conducted using CERR, a custom
written software package for evaluating radiotherapy plans [16].Patient assessment and follow-up
Patients were clinically assessed by an experienced radiation
oncologist at baseline, weekly during radiotherapy, and 2 weeks
and 3 months following completion of radiotherapy for acutetoxicity. The Common Terminology Criteria for Adverse Events ver-
sion 3.0 (NCI CTCAE v3.0) was used to grade acute toxicity, and the
worst toxicity was considered the ﬁnal toxicity [17]. Speciﬁcally for
acute toxicity, the presence of radiation dermatitis (skin erythema,
dry, moist, patchy or conﬂuent desquamation, and breast edema)
was documented and graded.
Cosmetic outcome was initially captured at baseline (post-sur-
gery, pre-radiotherapy), with late toxicity and cosmetic outcome
subsequently evaluated 6 months post-radiotherapy and 6-
monthly thereafter. The European Organization for Research and
Treatment of Cancer (EORTC) Breast Cancer Rating System for cos-
metic results of breast-conserving treatment was used at each of
these assessments [18]. This rates the appearance of the treated
breast as compared with the untreated breast, including breast size
and shape, location and shape of the areola and nipple, the pres-
ence of skin discoloration, telangiectasia, edema, or pallor, scar
appearance, and overall grade. The presence of pain, palpable ﬁbro-
sis of the whole breast and lumpectomy site, graded according to
the CTCAE v3.0, in addition to two items from the RTOG/EORTC late
radiation toxicity scale assessing skin and subcutaneous morbidity,
were also included in the late toxicity assessment.Workload impact
All planning and treatment times were recorded for each case,
and compared to those for SBT.Statistical analysis
The non-parametric McNemar’s exact test (one-sided) was used
to determine if the number of protocol deviations between the two
techniques was signiﬁcant. The Wilcoxon signed-rank sum test
(two-sided) for paired samples was used to determine whether
the difference in the median value of each of the dose-volume
parameters for the target and OARs was signiﬁcant between the
two techniques. Although not a pre-speciﬁed endpoint, the Wilco-
xon-Mann–Whitney test was used to compare factors that may be
associated with moist desquamation.
Results
Patient and tumor characteristics
The characteristics of the treated breast and tumor cavity are
summarized in Table 2. Median patient age was 52.4 years. All pa-
tients had good performance status (ECOG 0–1), and there were no
current smokers in the cohort. Eleven right-sided and four left-
sided tumors were treated. Tumor stage was Tis, T1, and T2, in
two (13.3%), 11 (73.3%), and two (13.3%) patients, respectively.
Only two (13.3%) patients had axillary node-positive disease. All
invasive tumors were invasive ductal carcinomas. Estrogen-recep-
tor status was positive in 14 (93.3%) patients. Negative surgical
margins were achieved in all patients; the resection margin status
was 61 mm, 1.1–2 mm, and >2 mm in seven (46.7%), two (13.3%),
92 Hypofractionated concomitant breast boostand six (40%) patients, respectively. Five (33.3%) patients received
adjuvant systemic chemotherapy and 11 (73.3%) received hor-
monal therapy. One patient had a post-operative seroma requiring
aspiration before simulation.Target dosimetry
A comparison of dose-volume parameters between the two
techniques is summarized in Table 3. All 15 CBRT plans satisﬁed
the dosimetric constraints, while SBT could not meet dosimetric
requirements in eight plans (53.3%). CTVboost V49.9Gy was greater
than 99%, as per protocol speciﬁcations, in all 15 CBRT plans, as
compared with 10 SBT plans (one-sided, p = 0.03). Median CTVboost
V49.9Gy was higher using CBRT, (median 100, range 99.7–100), as
compared with SBT (median 99.5, range 84.2–100, p = 0.004). DEV-
boost V49.9Gy was greater than 95%, as per protocol speciﬁcations, in
all 15 CBRT plans, compared to 12 SBT plans (one-sided, p = 0.125).
Median DEVboost V49.9Gy was higher using CBRT (median 99.6, range
97.4–100), compared to SBT (median 98.71, range 78.39–100,
p = 0.019). In ﬁve plans, SBT had inferior CTVboost coverage, partic-
ularly for deep surgical cavities.OAR dosimetry
OAR dosimetry is summarized in Table 4. We observed a statis-
tically signiﬁcant dose reduction to each of the ipsilateral and con-
tralateral lungs, and heart (with right-sided breast irradiation),
using CBRT when analyzed for all dose-volume parameters. The
maximum or average dose delivered to each of these organs was
consistently higher with SBT, compared with CBRT. No statistically
signiﬁcant difference was identiﬁed between techniques and the
maximum contralateral breast dose, or the dose-volume parame-
ters of the heart for left-sided breast irradiation. The contralateral
maximum breast doses were very low with both techniques (range
1.1–3.0 Gy). Similarly, mean heart dose, V10Gy and V25Gy for left-
sided breast irradiation were well below the protocol constraints
with both techniques. It is difﬁcult to make any ﬁrm conclusions
regarding this lack of a signiﬁcant difference however, due to the
small sample size.Table 2
Characteristics of treated breast and tumor cavity.
Median (Range)
Separation of treated breast at midline (mm) 180.0 (129.0, 284.0)
Volume of treated breast (ml)a 562.2 (178.9, 2046.7)Acute toxicity
Two weeks post-radiotherapy, four (27%) patients had grade 2
radiation dermatitis, deﬁned as moderate to brisk erythema with
patchy desquamation at the skin folds or creases. One (7%) patient
developed grade 3 radiation dermatitis at 1-month follow-up. This
patient had a 6.3 cm DCIS, had required two lumpectomies to
achieve clear margins, and her wound dehisced after completing
radiotherapy. The second assessment for acute toxicity took place,
on average, 90 days post-radiotherapy. No patients had any resid-
ual toxicity.
We did not identify an association between acute toxicity and
chemotherapy, although there was a suggestion of a possible asso-
ciation between grade 2 radiation dermatitis and larger surgical
cavity volumes. Patients who developed grade 2 radiation derma-
titis had a median cavity volume of 8.6 cm3 compared with
2.6 cm3 for those who did not (p = 0.10). Patients who developed
grade 2 radiation dermatitis were also of younger age (median
age 46 years vs. 55 years, p = 0.04).Depth of surgical cavity (mm)b 40.0 (8, 78.0)
Volume of surgical cavity (ml)a 3.9 (0.8, 27.7)
a Volumes of treated breast and surgical cavity were calculated electronically as
the volume of delineated breast or seroma respectively on the simulation CT
(Pinnacle, version 8).
b Cavity depth was measured from the skin surface to the deepest part of the
cavity using the CT simulation axial images.Late toxicity and cosmesis
One-year late toxicity data are available on all 15 patients
(Table 5). No grade 3–4 toxicity has occurred. A 50% increase in
overall grade 2 toxicity was identiﬁed at 1 year (2 vs. 4 patients),
though an improvement in overall grade 1 toxicity occurred frombaseline to 1 year. Grade 2 palpable induration (ﬁbrosis) of both
the lumpectomy site and whole breast was found to improve how-
ever, at 1 year when compared to baseline. The maximal morbidity
score for skin and subcutaneous tissues was grade 1 at 1 year.Treatment times
CBRT treatment planning took an average of 3 h, due to the
planning criteria deﬁned for breast IMRT boost plans. SBT required
an average of 45 min. Daily CBRT treatment time, including CBCT
veriﬁcation, required 45 min on Day 1, and 30 min thereafter. Con-
versely, SBT occupied 20 min per day. Overall treatment time how-
ever, was reduced by 5 days using CBRT compared with SBT.Discussion
Although a breast boost can signiﬁcantly improve local control,
different strategies are used to deﬁne the boost target volume, and
dose-fractionation and sequencing schedules vary. There are also
differences in planning and treatment techniques [2,3]. This study
used the highest boost dose per fraction of 3.28 Gy reported to
date. This did not appear to be associated with excessive normal
tissue morbidity. Several randomized controlled studies support
hypofractionation in adjuvant breast radiotherapy, demonstrating
equivalent rates of local control and long term cosmetic results
[7–9,19]. With a/b ratio of 4 Gy for tumor control and 3.4 Gy for
late cosmesis, our dose-fractionation schedule is biologically com-
parable to the EORTC 22881 study [2] (Table 1). In the United King-
dom, the IMPORT HIGH trial is comparing standard WBI, using a
hypofractionated regime of 40 Gy in 15 fractions of 2.67 Gy each
plus a sequential boost of 16 Gy in eight fractions, against two con-
comitant boost treatment arms using IMRT. The ﬁrst arm delivers a
concomitant boost of 3.2 Gy per fraction to the tumor cavity, while
the second delivers a concomitant boost of 3.5 Gy per fraction. We
await with interest the results of this important study.
A concomitant boost offers several important advantages. The
main practical advantage is the dramatic reduction in overall treat-
ment time; in our study treatment is only half as long as the EORTC
22881-10882 boost study (3.2 vs. 6.5 weeks). When compared
with a sequential boost schedule using 5–8 fractions, following
16 fractions of hypofractionated WBI, this concomitant boost tech-
nique reduces overall treatment time by 1–1.6 weeks. This im-
proves patient convenience and may improve compliance and
utilization of BCS [19–23]. In addition, an overall treatment time
of only 3.2 weeks might facilitate the delivery of radiotherapy prior
to delivery chemotherapy.
CBRT has superior dosimetry, with improved boost coverage,
and improved OAR sparing compared with SBT. Under-coverage
using SBT was observed when the surgical cavity was deep within
the breast or close to the chest wall, demonstrating the limitation
of this commonly used boost technique. The observed rates of
acute toxicity are comparable to historical reports using more con-
Table 3
Comparison of boost dose-volume parameters for CBRT and SBT techniques.
Boost target
volume
Dose-volume
parameter
Protocol
constraint
CBRT SBT p-valuea CBRT SBT p-
valuebNo. achieving
(%)
No. achieving (%) Median (range) Median (range)
CTVboost V49.9Gy (%) >99% 15 (100) 10 (67%) 0.03 100.0 (99.7, 100.0) 99.5 (84.2, 100.0) 0.004
D99 (Gy) 49.9 Gy 15 (100) 10 (67%) 0.03 51.1 (50.4, 52.2) 50.6 (48.5, 51.2) 0.0017
DEVboost V49.9Gy (%) >95% 15 (100) 12 (80%) 0.13 99.6 (97.4, 100.0) 98.7 (78.4, 100.0) 0.019
D99 (Gy) No constraint n/a n/a n/a 50.4 (49.6, 52.1) 49.9 (47.3, 51.1) 0.0009
Abbreviations: CTV, clinical target volume; DEV, dose evaluation volume; V49.9, percent volume of target receiving 49.9 Gy (95% of the prescribed dose); D99, minimum dose
covering 99% of the volume.
a McNemar exact one-sided p-value.
b Wilcoxon signed-rank sum test; n/a, not applicable.
Table 4
Comparison of normal tissue parameters for CBRT and SBT techniques.
Organs at risk Dose-volume parameter Protocol constraint n CBRT SBT Paired difference p-
valuea,bMedian (range) Median (range) Median (range)
Heart (when left breast is treated) Mean dose (Gy) <15 4 2.2 (2.0, 3.2) 3.2 (2.2, 4.2) 0.71 (1.96, 0.09) 0.13
Max dose (Gy) – 4 41.0 (34.7, 47.3) 42.1 (33.2, 44.3) 1.15 (3.7, 3.8) 0.63
V10Gy <20% 4 3.1 (2.4, 4.5) 4.0 (2.8, 6.0) 0.44 (2.7, 0.11) 0.13
V25Gy <10% 4 1.6 (0.8, 2.6) 1.7 (0.8, 2.5) 0.02 (0.35, 0.15) 0.26
Heart (when right breast is treated) Mean dose (Gy) – 11 0.6 (0.4, 1.5) 1.2 (0.5, 2.5) 0.48 (1.74, 0.06) 0.001
Max dose (Gy) <5 11 1.9 (1.4, 4.4) 5.0 (2.6, 6.7) 2.6 (3.8, 0.9) 0.001
Ipsilateral lung Mean dose (Gy) <20 15 5.5 (3.4, 6.6) 6.5 (4.2, 8.2) 1.30 (2.64, 0.02) <0.0001
V15Gy <15% 15 9.8 (4.5, 13.3) 10.3 (5.3, 16.0) 1.06 (2.77, 0.28) <0.0001
V20Gy – 15 8.2 (3.5, 11.7) 8.8 (3.9, 13.0) 0.71 (1.84, 0.16) <0.0001
Contralateral lung Max dose (Gy) <5 15 1.3 (0.5, 4.3) 2.2 (0.6, 4.9) 0.77 (2.68, 0.002) <0.0001
Contralateral breast Max dose (Gy) <5 15 2.0 (1.1, 2.9) 2.0 (1.3, 3.0) 0.05 (1.14, 0.75) 0.450
Abbreviations: Max, maximum; VxGy, percent volume of organ receiving Px Gy.
a Wilcoxon signed-rank sum test.
b p-value not adjusted.
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niques [12]. Cosmesis and long term toxicity at 1 year are similar
to other publications.
To date, at least 15 reports have described clinical or radiation
planning experiences with CBRT, in the context of local control,
toxicity, and dosimetric coverage [24–39]. Overall, CBRT has been
observed to be feasible and safe, although there have been widely
varying treatment techniques and doses with total plus boost reg-
imens ranging from 44 Gy in 16 fractions over 3.2 weeks, to
73.78 Gy in 31 fractions over 5.6 weeks [37–38] (Supplementary
Table 1). With the exception of two studies [29–30], all others
delivered the concomitant boost daily with WBI. Only one study
delivered more than 3 Gy per fraction [28]. This contrasts with
our schedule of 52.4 Gy in 16 fractions.
All CBRT studies report similar or better acute toxicity when
compared with matched controls using a conventional sequential
boost, with a 23–45% incidence of grade 2 skin toxicity, consistent
with our observations [24–30]. With grade 3 moist desquamation
occurring in only 1 (7%) patient in our study, this compares favor-
ably with a moist desquamation rate of 31% in a randomised trial
of breast IMRT [12]. Morganti et al. reported an association be-
tween increased rates of acute toxicity with both larger tumor-
bed volumes, and previous use of chemotherapy [37]. In our anal-
ysis, a possible association between increased acute toxicity and
both larger cavity volumes and younger age was identiﬁed. No def-
inite conclusions can be made regarding these observations how-
ever, given the small sample size.
The majority of patients treated with CBRT in our study had
overall grade 0–1 (73.4%) cosmetic outcome at 1 year (Table 5).While four patients were judged as having overall grade 2 cosmetic
result at 1 year, this only represented an additional two patients
compared with baseline, and consisted of an alteration in breast
shape in one patient and breast edema in another. This highlights
the importance of including both surgical and radiotherapy out-
comes in the assessment of late toxicity and cosmesis after BCS.
This is further substantiated by the absence of RTOG/EORTC grade
2–3 toxicity of the skin and subcutaneous tissues, at 1 year com-
pared to baseline, and the improvement in CTCAE v3.0 grade 2 pal-
pable induration (ﬁbrosis). Grade 1 toxicity was increased at 1 year
but was in keeping with the other reports [24,26,29,32,40,41].
Mayo et al., with a median follow-up of 11 months, reported excel-
lent cosmetic results in all 120 patients who received a concomi-
tant daily boost of 0.2 Gy, plus a ﬁnal 10 Gy boost also to the
boost target volume [26]. McDonald et al. reported good or excel-
lent global breast cosmetic score in 96.5% of 142 cases with a min-
imum of 3 years follow-up [32]. Bantema-Joppe et al. reported a
3 year locoregional control rate of 99.2% in a retrospective review
of 752 patients who received a 3D-conformal hypofractionated
simultaneous integrated boost of 2.3–2.4 Gy to the boost volume
in 28 fractions (Total boost dose 64.4–67.2 Gy). Grade P2 ﬁbrosis
and breast edema occurred in 9.1% and 10.7% of patients, respec-
tively [39]. Corvo et al. evaluated the feasibility of a concomitant
boost of 1.2 Gy delivered once weekly [40]. At 2 years follow-up,
cosmesis was excellent or good in 95% of patients. Late toxicity
was grade 0 in 92%, grade 1 in 7% and grade 2 in 1%. Guenzi et
al. delivered 39 Gy in 13 fractions four times per week to the whole
breast and a weekly 3D-conformal concomitant boost on Mondays
of 1 Gy, immediately following WBI [41]. Subacute toxicity at
Table 5
Cosmetic outcome and late toxicity.
Baselinea (%) 1 year (%)
Overall gradeb
0 2 (13.3) 7 (46.7)
1 11 (73.3) 4 (26.7)
2 2 (13.3) 4 (26.7)
3–4 0 0
Palpable induration (ﬁbrosis) of lumpectomy site (grade)c
0 2 (13.3) 7 (46.7)
1 5 (33.3) 7 (46.7)
2 8 (53.3) 1 (6.7)
3–4 0 0
Palpable induration (ﬁbrosis) of whole breast (grade)c
0 12 (80) 8 (53.3)
1 2 (13.3) 6 (40)
2 2 (13.3) 1 (6.7)
3–4 0 0
Pain (grade)c
0 9 (60) 5 (33.3)
1 6 (40) 9 (60)
2 0 1 (6.7)
3–4 0 0
Morbidity score for skin (grade)d
0 15 (100) 10 66.7)
1 0 5 (33.3)
2 0 0
3–4 0 0
Morbidity score for subcutaneous tissue (grade)d
0 3 (20) 7 (46.7)
1 9 (60) 8 (53.3)
2 3 (20) 0
3–4 0 0
a Baseline toxicity was assessed post-surgery, pre-radiotherapy.
b Graded according to the European Organization for Research and Treatment of
Cancer (EORTC) Breast Cancer Rating System for cosmetic results of breast-con-
serving treatment (assesses breast size and shape, location and shape of nipple and
areola, skin pallor and discolouration, presence of edema or telangiectasia, scar
appearance).
c Graded according to Common Terminology Criteria for Adverse Events v3.0
(CTCAE).
d Graded according to the RTOG/EORTC late radiation toxicity scale.
94 Hypofractionated concomitant breast boost6 months showed grades 1 and 2 hyperpigmentation in 34% and 6%
of patients, respectively, with no grade 3 or 4 toxicity at 6, 12, or
24 months. Grades 1 and 2 late toxicity at 24 months was 45%
and 3%, respectively. There have been no recurrences in our study
which is consistent with other CBRT reports [26,28,37]; Formenti
et al. reported only one regional recurrence among a cohort of 91
patients [28].
Most studies delivering CBRT have used IMRT or segmented
tangential ﬁelds to deliver WBI and conformal photons for boost
delivery [24–26,28,29,37]. However, Jalali et al. and Freedman et
al. used non-segmented tangents for WBI and electrons for the
boost [30,27]. Although no increased acute toxicity was reported
in these two studies, it is generally observed that IMRT allows bet-
ter coverage and dose homogeneity, compared with non-IMRT
techniques [26,35–37,42]. Importantly, dose to critical organs such
as the heart and lungs are lower with an IMRT technique, consis-
tent with our own observations [35]. Given that this is a relatively
young cohort of patients with excellent prognosis, every effort
should be made to limit dose to normal structures [43,44].
Planning of CBRT took longer than that of SBT, as did treatment
delivery of CBRT. The reasons for the longer daily treatment times
observed with CBRT are probably explained by the additional ﬁelds
and non-coplanar beams required for CBRT. Also, as the CBRT tech-
nique was not a fully integrated one-chain delivery of all WBI and
boost segments, CBCT veriﬁcation of treatment position was
required for both WBI and the boost separately.Limitations of our study include the small sample size and rel-
atively short follow-up. Nonetheless, our toxicity data demonstrat-
ing the feasibility of delivering this hypofractionated concomitant
boost schedule are very encouraging.Conclusions
This feasibility study of concomitant boost radiotherapy using
IMRT demonstrates excellent dosimetric coverage of the boost vol-
ume, with better sparing of normal tissue, compared to SBT using
direct appositional mixed photon/electrons. Follow-up data show
acceptable acute and long-term toxicity proﬁles using this hypo-
fractionated approach, wherein the boost volume received a daily
dose of 3.28 Gy in 16 fractions over 3.2 weeks, the largest thus
far reported in the literature. While more upfront resources are
needed for planning and treatment with this technique, the overall
treatment course was reduced by 1 week.Conﬂict of interest
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